| US 7,456,283 B2 | ||
| N-phenyl-2-pyrimidine-amine derivatives | ||
| Olivier Loiseleur, Saint-Louis (France); Daniel Kaufmann, Therwil (Switzerland); Stephan Abel, Weil am Rhein (Germany); Hans Michael Bürger, Allschwil (Switzerland); Mark Meisenbach, Durmenach (France); Beat Schmitz, Allschwil (Switzerland); and Gottfried Sedelmeier, Schallstadt (Germany) | ||
| Assigned to Novartis AG, Bassel (Switzerland) | ||
| Appl. No. 10/503,538 PCT Filed Feb. 06, 2003, PCT No. PCT/EP03/01188 § 371(c)(1), (2), (4) Date Jan. 20, 2005, PCT Pub. No. WO03/066613, PCT Pub. Date Aug. 14, 2003. |
||
| Claims priority of application No. 0202873.6 (GB), filed on Feb. 07, 2002. | ||
| Prior Publication US 2006/0142580 A1, Jun. 29, 2006 | ||
| Int. Cl. C07D 241/04 (2006.01); C07D 295/00 (2006.01) | ||
| U.S. Cl. 544—358 [544/400] | 4 Claims |
1. A compound of formula I
 R3 is (4-methyl-piperazinyl)-methyl and
R1, R2, R4 and R5 are independently hydrogen, cyano; lower alkyl; hydroxy- or amino-substituted lower alkyl; trifluoromethyl; free, etherified
or esterified hydroxy; lower alkoxy; lower alkanoyloxy; free, alkylated or acylated amino; mono- or di-lower alkylamino; lower
alkanoylamino; benzoylamino; free or esterified carboxy; lower alkoxycarbonyl and halogen;
R6 is halogen, NH2, NO2, NHC(O)CF3, NHC(O)CH3, or NHC(NH)NH2, R7 is methyl and R8 is hydrogen;
or a salt or crystal form thereof.
|